Skip to main content

Table 2 Demographic and clinical data of the iNPH patient subgroups by CSF Aβ42 level (N = 25)

From: Evaluation of coexistence of Alzheimer’s disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers

 

Lower CSF Aβ42

Higher CSF Aβ42

p-value

n (M/F)

8 (3/5)

17 (9/8)

0.673

Age, yr

76.1 ± 7.3

72.0 ± 6.7

0.187

Education, yr

7.7 ± 5.6

8.7 ± 5.2

0.687

K-MMSE

16.8 ± 6.6

20.8 ± 6.9

0.193

Disease duration, day

724.1 ± 513.6

769.4 ± 520.4

0.857

Aβ42, pg/ml

368.7 ± 72.3

679.1 ± 121.7

<0.001*

T-tau, pg/ml

145.7 ± 103.9

125.3 ± 64.6

0.551

P-tau, pg/ml

28.2 ± 13.8

26.4 ± 7.3

0.682

Evans ratio

0.34 ± 0.02

0.36 ± 0.03

0.277

DWMH

1.6 ± 0.9

1.5 ± 0.8

0.804

PVWMH

2.0 ± 0.7

1.9 ± 0.7

0.856

Hippocampal atrophy

1.6 ± 0.9

0.7 ± 0.6

0.020*

Pre-gait score

2.75 ± 1.48

2.59 ± 1.54

0.807

Pre-urinary score

1.00 ± 1.06

0.94 ± 0.96

0.892

Pre-cognition score

1.50 ± 0.75

1.41 ± 0.79

0.795

Pre-iNPH score sum

4.13 ± 2.94

3.94 ± 2.86

0.883

Post-gait score

2.00 ± 1.69

2.00 ± 1.11

1.000

Post-urinary score

0.63 ± 1.06

0.47 ± 0.80

0.689

Post-cognition score

1.38 ± 0.91

1.12 ± 0.78

0.474

Post-iNPH score sum

3.00 ± 3.38

2.65 ± 2.14

0.753

Gait score improvement

0.75 ± 0.70

0.59 ± 0.87

0.651

Urinary score improvement

0.38 ± 0.74

0.47 ± 0.71

0.761

Cognition score improvement

0.13 ± 0.35

0.29 ± 0.47

0.377

iNPH score improvement

1.25 ± 1.48

1.29 ± 0.68

0.950

  1. Continuous variables are presented as mean ± standard deviation. iNPH: Idiopathic Normal Pressure Hydrocephalus; AD: Alzheimer’s Disease; M: Male; F: Female; K-MMSE: Korean version of Mini Mental Status Exam; PVWMH: Periventricular White Matter Hyperintensity; DWMH: Deep White Matter Hyperintensity. *p < 0.05.